← Back to Search

Tyrosine Kinase Inhibitor

Lenvatinib for Pheochromocytoma

Phase 2
Waitlist Available
Led By Ashish Chintakuntlawar
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Study Summary

This trial studies the effectiveness of lenvatinib in treating patients with pheochromocytoma or paraganglioma.

Eligible Conditions
  • Pheochromocytoma
  • Paraganglioma
  • Adrenal Gland Pheochromocytoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Confirmed Tumor Response Rate
Secondary outcome measures
Duration of Tumor Response
Overall Survival Time
Patients Evaluable for Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events Version 4.0
+2 more
Other outcome measures
Changes in Urinary Catecholamine and Metanephrine Levels
Germline Mutational Status in Peripheral Blood Mononuclear Cells
Peripheral blood mononuclear cell (cell)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (lenvatinib)Experimental Treatment3 Interventions
Patients receive lenvatinib PO once daily on days 1-28. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lenvatinib
2005
Completed Phase 4
~2690

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,221 Previous Clinical Trials
3,769,137 Total Patients Enrolled
1 Trials studying Pheochromocytoma
96 Patients Enrolled for Pheochromocytoma
National Cancer Institute (NCI)NIH
13,680 Previous Clinical Trials
40,928,516 Total Patients Enrolled
19 Trials studying Pheochromocytoma
1,658 Patients Enrolled for Pheochromocytoma
Ashish ChintakuntlawarPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
3 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
2017. "Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03008369.
~0 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top